scholarly journals Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Hyung Suk Kim ◽  
Ja Hyeon Ku
Keyword(s):  
Inflammatory Response ◽  
Cancer Patients ◽  
Systemic Inflammatory Response ◽  
Neutrophil To Lymphocyte Ratio ◽  
Oncologic Outcomes ◽  
Survival Outcomes ◽  
Lymphocyte Ratio ◽  
The Past ◽  
Differential White Blood Cell

A growing body of evidence suggests that systemic inflammatory response (SIR) in the tumor microenvironment is closely related to poor oncologic outcomes in cancer patients. Over the past decade, several SIR-related hematological factors have been extensively investigated in an effort to risk-stratify cancer patients to improve treatment selection and to predict posttreatment survival outcomes in various types of cancers. In particular, one readily available marker of SIR is neutrophil-to-lymphocyte ratio (NLR), which can easily be measured on the basis of absolute neutrophils and absolute lymphocytes in a differential white blood cell count performed in the clinical setting. Many investigators have vigorously assessed NLR as a potential prognostic biomarker predicting pathological and survival outcomes in patients with urothelial carcinoma (UC) of the bladder. In this paper, we aim to present the prognostic role of NLR in patients with UC of the bladder through a thorough review of the literature.

scholarly journals Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy

Medicine ◽  
2019 ◽  
Vol 98 (1) ◽  
pp. e13842 ◽  
Author(s):  
Ling Bo Xue ◽  
Yong Hong Liu ◽  
Bo Zhang ◽  
Yan Fang Yang ◽  
Dong Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Breast Cancer Patients ◽  
Prognostic Role ◽  
Lymphocyte Ratio

Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16050-e16050
Author(s):  
Atike Pinar ◽  
Ahmet Ozveren ◽  
Zeki Gokhan Surmeli ◽  
Ulus Ali Sanli ◽  
Ruchan Uslu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Castration Resistant Prostate Cancer ◽  
Prognostic Role ◽  
Lymphocyte Ratio ◽  
Castration Resistant

scholarly journals Role of Monocyte Count and Neutrophil-to-Lymphocyte Ratio in Survival of Oral Cancer Patients

2016 ◽  
Vol 21 (01) ◽  
pp. 21-27 ◽  
Author(s):  
Saurabh Bobdey ◽  
Balasubramaniam Ganesh ◽  
Prabhashankar Mishra ◽  
Aanchal Jain
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Neutrophil To Lymphocyte Ratio ◽  
Monocyte Count ◽  
Lymphocyte Ratio ◽  
Oral Cancer Patients

scholarly journals Serum inflammation-based scores in endocrine tumors

2021 ◽  
Author(s):  
Pedro Marques ◽  
Friso de Vries ◽  
Olaf M Dekkers ◽  
Márta Korbonits ◽  
Nienke R Biermasz ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Evidence Synthesis ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Endocrine Tumor ◽  
Systemic Inflammatory Response ◽  
Neutrophil To Lymphocyte Ratio ◽  
Endocrine Surgery ◽  
Endocrine Tumors ◽  
Lymphocyte Ratio

Abstract Context Serum inflammation-based scores reflect systemic inflammatory response and/or patients’ nutritional status, and may predict clinical outcomes in cancer. While these are well-described and increasingly used in different cancers, their clinical usefulness in the management of patients with endocrine tumors is less known. Evidence acquisition A comprehensive PubMed search was performed using the terms “endocrine tumor”, “inflammation”, “serum inflammation-based score”, “inflammatory-based score”, “inflammatory response-related scoring”, “systemic inflammatory response markers”, “Neutrophil-to-lymphocyte ratio”, “Neutrophil-to-platelet ratio”, “Lymphocyte-to-monocyte ratio”, “Glasgow Prognostic Score”, “Neutrophil-Platelet Score”, “Systemic Immune-Inflammation Index”, and “Prognostic Nutrition Index” in clinical studies. Evidence synthesis The Neutrophil-to-Lymphocyte Ratio and the Platelet-to-Lymphocyte Ratio are the ones most extensively investigated in patients with endocrine tumors. Other scores have also been considered in some studies. Several studies focused in finding whether serum inflammatory biomarkers may stratify the endocrine tumor patients’ risk and detect those at risk for developing more aggressive and/or refractory disease, particularly after endocrine surgery. Conclusions In this review, we summarize the current knowledge on the different serum inflammation-based scores and their usefulness in predicting the phenotype, clinical aggressiveness, disease outcomes and prognosis in patients with endocrine tumors. The value of such serum inflammation-based scores in the management of patients with endocrine tumors has been emerging over the last decade. However, further research is necessary to establish useful markers and their cut-offs for routine clinical practice for individual diseases.

The prognostic role of neutrophil-to-lymphocyte ratio trends during therapy in esophageal cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 17-17 ◽  
Author(s):  
Yaseen Al Lawati ◽  
Jose Luis Ramirez-Garcialuna ◽  
Juan Carlos Molina Franjola ◽  
Donavan Pham ◽  
Elena Skothos ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Cancer Progression ◽  
Advanced Disease ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Oncologic Outcomes ◽  
Prognostic Role ◽  
Lymphocyte Ratio

17 Background: Neutrophil-to-lymphocyte ratio (NLR) has been identified as a biomarker for a number of malignancies, with higher ratios being associated with poorer oncologic outcomes. Rather than purely an indicator of advanced disease there is emerging evidence that neutrophils are directly implicated in facilitating cancer progression, and thus alterations and trends of neutrophil counts and NLR during different phases of treatment may reflect a change in oncologic outcome that is as important, or more so, as the absolute count or NLR at baseline. The aim of this study is to investigate the prognostic role of neutrophil-to-lymphocyte ratio trends during the treatment trajectory of patients with esophageal adenocarcinoma. Methods: This is a retrospective study of patients who underwent esophagectomy for esophageal adenocarcinoma between 2005-2016. NLR was measured at three time points: baseline, during neoadjuvant chemotherapy (NAC), and in the late postoperative period. Primary outcomes were overall (OS) and disease-free survival (DFS). Results: 333 patients met our inclusion criteria. Mean age was 65.6 years and 82% of patients were males. The majority of patients had locally advanced disease; 75% had clinical T3 disease and 59% had clinical N-positive disease. NAC was administered in 65.6% of patients. Increasing NLR trends between baseline and late postoperative periods was associated with worse OS (3-year OS 56.1% vs. 71.9%, p=0.045). Patients in the high NLR group before and after treatment did worse than those who moved from high to low groups (3-year OS 42.8% vs. 69.2%, p=<0.0001, 3-year DFS 32.3% vs. 61.8%, p=0.0001). High NLR at baseline and in the postoperative stage is associated with worse OS (3-year OS: 57% vs. 75.7% for baseline and 44.1% vs. 74.9% for postoperative NLR; p=0.0038 and <0.0001, respectively) and DFS (3-year DFS: 52.4% vs. 60.9% for baseline and 34.9% vs. 59.9% for postoperative NLR; p=0.03 and <0.0001, respectively). Patients with complete pathological response to NAC had lower mean baseline NLR (3.2 vs. 4.9 p=0.009). Conclusions: Changes in NLR during treatment may provide a clearer picture about survival outcomes and the role of neutrophils in cancer progression.

Sign in / Sign up

Export Citation Format

Share Document